Symptomatic radiation necrosis in brain metastasis patients treated with stereotactic radiosurgery and immunotherapy

Noah Weingarten, Tim J. Kruser, Orin Bloch

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objectives: The association of symptomatic radiation necrosis (RN) with stereotactic radiosurgery (SRS) and immune checkpoint inhibitors (ICIs) in brain metastases patients has been incompletely explored. We aim to discuss the incidence, risk factors, and prognosis of symptomatic RN in patients treated with these modalities. Patients and methods: We retrospectively evaluated the incidence of symptomatic RN among all patients with brain metastases treated with both SRS and an ICI at a single academic center. Risk factors for the development of symptomatic RN were determined, along with median overall survival (OS) stratified by the development of RN. Results: Between 2010 and 2016, 57 brain metastases patients were treated with both SRS and an ICI. Only 4 (7%) developed symptomatic RN. Symptomatic RN lesions were more likely to be located in the cerebral cortex (p = 0.019) and be associated with a primary renal cell carcinoma (p = 0.032). Median OS was 32 months for those who developed symptomatic RN and 29 months for all other patients (p = 0.16). Conclusion: Treatment of brain metastases with both SRS and an ICI is an effective modality that poses mild risk for developing symptomatic RN when compared to the risk of RN from SRS alone.

Original languageEnglish (US)
Pages (from-to)14-18
Number of pages5
JournalClinical Neurology and Neurosurgery
Volume179
DOIs
StatePublished - Apr 2019
Externally publishedYes

Fingerprint

Radiosurgery
Immunotherapy
Necrosis
Radiation
Neoplasm Metastasis
Brain
Survival
Incidence
Renal Cell Carcinoma
Cerebral Cortex

Keywords

  • Brain metastasis
  • Immunotherapy
  • Neuroimaging
  • Radiation necrosis
  • Stereotactic radiosurgery

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

Symptomatic radiation necrosis in brain metastasis patients treated with stereotactic radiosurgery and immunotherapy. / Weingarten, Noah; Kruser, Tim J.; Bloch, Orin.

In: Clinical Neurology and Neurosurgery, Vol. 179, 04.2019, p. 14-18.

Research output: Contribution to journalArticle

@article{883b7433ed7a4d35a0dc9a71d1b093bc,
title = "Symptomatic radiation necrosis in brain metastasis patients treated with stereotactic radiosurgery and immunotherapy",
abstract = "Objectives: The association of symptomatic radiation necrosis (RN) with stereotactic radiosurgery (SRS) and immune checkpoint inhibitors (ICIs) in brain metastases patients has been incompletely explored. We aim to discuss the incidence, risk factors, and prognosis of symptomatic RN in patients treated with these modalities. Patients and methods: We retrospectively evaluated the incidence of symptomatic RN among all patients with brain metastases treated with both SRS and an ICI at a single academic center. Risk factors for the development of symptomatic RN were determined, along with median overall survival (OS) stratified by the development of RN. Results: Between 2010 and 2016, 57 brain metastases patients were treated with both SRS and an ICI. Only 4 (7{\%}) developed symptomatic RN. Symptomatic RN lesions were more likely to be located in the cerebral cortex (p = 0.019) and be associated with a primary renal cell carcinoma (p = 0.032). Median OS was 32 months for those who developed symptomatic RN and 29 months for all other patients (p = 0.16). Conclusion: Treatment of brain metastases with both SRS and an ICI is an effective modality that poses mild risk for developing symptomatic RN when compared to the risk of RN from SRS alone.",
keywords = "Brain metastasis, Immunotherapy, Neuroimaging, Radiation necrosis, Stereotactic radiosurgery",
author = "Noah Weingarten and Kruser, {Tim J.} and Orin Bloch",
year = "2019",
month = "4",
doi = "10.1016/j.clineuro.2019.02.010",
language = "English (US)",
volume = "179",
pages = "14--18",
journal = "Clinical Neurology and Neurosurgery",
issn = "0303-8467",
publisher = "Elsevier",

}

TY - JOUR

T1 - Symptomatic radiation necrosis in brain metastasis patients treated with stereotactic radiosurgery and immunotherapy

AU - Weingarten, Noah

AU - Kruser, Tim J.

AU - Bloch, Orin

PY - 2019/4

Y1 - 2019/4

N2 - Objectives: The association of symptomatic radiation necrosis (RN) with stereotactic radiosurgery (SRS) and immune checkpoint inhibitors (ICIs) in brain metastases patients has been incompletely explored. We aim to discuss the incidence, risk factors, and prognosis of symptomatic RN in patients treated with these modalities. Patients and methods: We retrospectively evaluated the incidence of symptomatic RN among all patients with brain metastases treated with both SRS and an ICI at a single academic center. Risk factors for the development of symptomatic RN were determined, along with median overall survival (OS) stratified by the development of RN. Results: Between 2010 and 2016, 57 brain metastases patients were treated with both SRS and an ICI. Only 4 (7%) developed symptomatic RN. Symptomatic RN lesions were more likely to be located in the cerebral cortex (p = 0.019) and be associated with a primary renal cell carcinoma (p = 0.032). Median OS was 32 months for those who developed symptomatic RN and 29 months for all other patients (p = 0.16). Conclusion: Treatment of brain metastases with both SRS and an ICI is an effective modality that poses mild risk for developing symptomatic RN when compared to the risk of RN from SRS alone.

AB - Objectives: The association of symptomatic radiation necrosis (RN) with stereotactic radiosurgery (SRS) and immune checkpoint inhibitors (ICIs) in brain metastases patients has been incompletely explored. We aim to discuss the incidence, risk factors, and prognosis of symptomatic RN in patients treated with these modalities. Patients and methods: We retrospectively evaluated the incidence of symptomatic RN among all patients with brain metastases treated with both SRS and an ICI at a single academic center. Risk factors for the development of symptomatic RN were determined, along with median overall survival (OS) stratified by the development of RN. Results: Between 2010 and 2016, 57 brain metastases patients were treated with both SRS and an ICI. Only 4 (7%) developed symptomatic RN. Symptomatic RN lesions were more likely to be located in the cerebral cortex (p = 0.019) and be associated with a primary renal cell carcinoma (p = 0.032). Median OS was 32 months for those who developed symptomatic RN and 29 months for all other patients (p = 0.16). Conclusion: Treatment of brain metastases with both SRS and an ICI is an effective modality that poses mild risk for developing symptomatic RN when compared to the risk of RN from SRS alone.

KW - Brain metastasis

KW - Immunotherapy

KW - Neuroimaging

KW - Radiation necrosis

KW - Stereotactic radiosurgery

UR - http://www.scopus.com/inward/record.url?scp=85061634337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061634337&partnerID=8YFLogxK

U2 - 10.1016/j.clineuro.2019.02.010

DO - 10.1016/j.clineuro.2019.02.010

M3 - Article

C2 - 30784894

AN - SCOPUS:85061634337

VL - 179

SP - 14

EP - 18

JO - Clinical Neurology and Neurosurgery

JF - Clinical Neurology and Neurosurgery

SN - 0303-8467

ER -